These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

645 related items for PubMed ID: 21911045

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis.
    Sandborn WJ, Regula J, Feagan BG, Belousova E, Jojic N, Lukas M, Yacyshyn B, Krzeski P, Yeh CH, Messer CA, Hanauer SB.
    Gastroenterology; 2009 Dec; 137(6):1934-43.e1-3. PubMed ID: 19766640
    [Abstract] [Full Text] [Related]

  • 3. Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis.
    Miehlke S, Madisch A, Kupcinskas L, Petrauskas D, Böhm G, Marks HJ, Neumeyer M, Nathan T, Fernández-Bañares F, Greinwald R, Mohrbacher R, Vieth M, Bonderup OK, BUC-60/COC Study Group.
    Gastroenterology; 2014 May; 146(5):1222-30.e1-2. PubMed ID: 24440672
    [Abstract] [Full Text] [Related]

  • 4. Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis.
    Gibson PR, Fixa B, Pekárková B, Bátovský M, Radford-Smith G, Tibitanzl J, Gabalec L, Florin TH, Greinwald R.
    Aliment Pharmacol Ther; 2006 Apr 01; 23(7):1017-26. PubMed ID: 16573804
    [Abstract] [Full Text] [Related]

  • 5. Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis--additional results from two controlled studies.
    Sandborn WJ, Hanauer S, Lichtenstein GR, Safdi M, Edeline M, Scott Harris M.
    Aliment Pharmacol Ther; 2011 Oct 01; 34(7):747-56. PubMed ID: 21848857
    [Abstract] [Full Text] [Related]

  • 6. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial.
    Miner PB, Wedel MK, Xia S, Baker BF.
    Aliment Pharmacol Ther; 2006 May 15; 23(10):1403-13. PubMed ID: 16669955
    [Abstract] [Full Text] [Related]

  • 7. Mesalazine Modified-Release Tablet in the Treatment of Ulcerative Colitis in the Active Phase: A Chinese, Multicenter, Single-Blind, Randomized Controlled Study.
    Sun J, Yuan Y.
    Adv Ther; 2016 Mar 15; 33(3):400-9. PubMed ID: 26898569
    [Abstract] [Full Text] [Related]

  • 8. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
    Hanauer SB, Sandborn WJ, Kornbluth A, Katz S, Safdi M, Woogen S, Regalli G, Yeh C, Smith-Hall N, Ajayi F.
    Am J Gastroenterol; 2005 Nov 15; 100(11):2478-85. PubMed ID: 16279903
    [Abstract] [Full Text] [Related]

  • 9. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study.
    Scherl EJ, Pruitt R, Gordon GL, Lamet M, Shaw A, Huang S, Mareya S, Forbes WP.
    Am J Gastroenterol; 2009 Jun 15; 104(6):1452-9. PubMed ID: 19491859
    [Abstract] [Full Text] [Related]

  • 10. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.
    Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, Marano CW, Strauss R, Oddens BJ, Feagan BG, Hanauer SB, Lichtenstein GR, Present D, Sands BE, Sandborn WJ.
    Gastroenterology; 2011 Oct 15; 141(4):1194-201. PubMed ID: 21723220
    [Abstract] [Full Text] [Related]

  • 11. Mesalazine Modified-Release Tablet in the Treatment of Ulcerative Colitis in the Remission Phase: A Chinese, Multicenter, Single-Blind, Randomized Controlled Study.
    Sun J, Yuan Y.
    Adv Ther; 2016 Mar 15; 33(3):410-22. PubMed ID: 26905266
    [Abstract] [Full Text] [Related]

  • 12. Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis.
    Carbonnel F, Colombel JF, Filippi J, Katsanos KH, Peyrin-Biroulet L, Allez M, Nachury M, Novacek G, Danese S, Abitbol V, Bossa F, Moreau J, Bommelaer G, Bourreille A, Fumery M, Roblin X, Reinisch W, Bouhnik Y, Brixi H, Seksik P, Malamut G, Färkkilä M, Coulibaly B, Dewit O, Louis E, Deplanque D, Michetti P, Sarter H, Laharie D, European Crohn's and Colitis Organisation, Groupe d'Étude Thérapeutique des Affections Inflammatoires Digestives.
    Gastroenterology; 2016 Feb 15; 150(2):380-8.e4. PubMed ID: 26632520
    [Abstract] [Full Text] [Related]

  • 13. Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial.
    Raedler A, Behrens C, Bias P.
    Aliment Pharmacol Ther; 2004 Dec 15; 20(11-12):1353-63. PubMed ID: 15606398
    [Abstract] [Full Text] [Related]

  • 14. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.
    Marteau P, Probert CS, Lindgren S, Gassul M, Tan TG, Dignass A, Befrits R, Midhagen G, Rademaker J, Foldager M.
    Gut; 2005 Jul 15; 54(7):960-5. PubMed ID: 15951542
    [Abstract] [Full Text] [Related]

  • 15. 3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial.
    Gross V, Bunganic I, Belousova EA, Mikhailova TL, Kupcinskas L, Kiudelis G, Tulassay Z, Gabalec L, Dorofeyev AE, Derova J, Dilger K, Greinwald R, Mueller R, International BUC-57 Study Group.
    J Crohns Colitis; 2011 Apr 15; 5(2):129-38. PubMed ID: 21453882
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of Indigo Naturalis in a Multicenter Randomized Controlled Trial of Patients With Ulcerative Colitis.
    Naganuma M, Sugimoto S, Mitsuyama K, Kobayashi T, Yoshimura N, Ohi H, Tanaka S, Andoh A, Ohmiya N, Saigusa K, Yamamoto T, Morohoshi Y, Ichikawa H, Matsuoka K, Hisamatsu T, Watanabe K, Mizuno S, Suda W, Hattori M, Fukuda S, Hirayama A, Abe T, Watanabe M, Hibi T, Suzuki Y, Kanai T, INDIGO Study Group.
    Gastroenterology; 2018 Mar 15; 154(4):935-947. PubMed ID: 29174928
    [Abstract] [Full Text] [Related]

  • 17. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial.
    Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, Tsujikawa T, Fujiyama Y, Mitsuyama K, Sata M, Yamada M, Iwaoka Y, Kanke K, Hiraishi H, Hirayama K, Arai H, Yoshii S, Uchijima M, Nagata T, Koide Y.
    Clin Gastroenterol Hepatol; 2006 Dec 15; 4(12):1502-6. PubMed ID: 17101300
    [Abstract] [Full Text] [Related]

  • 18. Mesalazine granules are superior to Eudragit-L-coated mesalazine tablets for induction of remission in distal ulcerative colitis - a pooled analysis.
    Leifeld L, Pfützer R, Morgenstern J, Gibson PR, Marakhouski Y, Greinwald R, Mueller R, Kruis W.
    Aliment Pharmacol Ther; 2011 Nov 15; 34(9):1115-22. PubMed ID: 21923715
    [Abstract] [Full Text] [Related]

  • 19. [A multi-center randomized double-blinded, placebo-controlled clinical study on efficacy of composite sophora colon-soluble capsules in treating ulcerative colitis of internal dampness-heat accumulation syndrome type].
    Tong ZQ, Yang B, Tong XY.
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2011 Feb 15; 31(2):172-6. PubMed ID: 21425568
    [Abstract] [Full Text] [Related]

  • 20. A review of infliximab use in ulcerative colitis.
    Wilhelm SM, McKenney KA, Rivait KN, Kale-Pradhan PB.
    Clin Ther; 2008 Feb 15; 30(2):223-30. PubMed ID: 18343261
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.